What Daisy Genomics does

Daisy Genomics (formerly Armonica Technologies) is a privately held biotechnology company headquartered in Albuquerque, New Mexico, developing a proprietary optical long-read DNA/RNA sequencing platform for precision medicine applications. The company's core technology combines nanofabrication, semiconductor manufacturing processes, and surface-enhanced Raman spectroscopy (SERS) to enable direct detection of nucleic acids and epigenetic signals without chemical amplification. This physics-based approach is positioned to improve the accuracy, speed, and cost of detecting epigenetic biomarkers relative to traditional sequencing chemistries, with initial applications targeted at liquid biopsy-based early cancer detection and clinical diagnostics. The platform also integrates AI algorithms for genomic data analysis to support clinical workflow expansion.

Daisy Genomics pursues a partnership-driven, B2B go-to-market strategy targeting clinical diagnostics firms, healthcare providers, and academic research institutions. Revenue is anticipated from hardware sales of the sequencing platform and from licensing of downstream diagnostic tools, though no commercial revenue is currently disclosed. Anchor collaborations include New Day Diagnostics (with the University of Tennessee and East Tennessee Health Innovation Alliance) for colorectal cancer liquid biopsy development, and Oak Ridge National Laboratory's Center for Nanophase Materials Sciences for nanofabrication capability access. The company has raised approximately $8.45 million cumulatively across multiple rounds between 2017 and 2025, including a $2.5M seed financing in December 2025 led by Cottonwood Technology Fund, Tramway Venture Partners, and Waves Capital Partners, supplemented by non-dilutive grants from the National Human Genome Research Institute. Leadership comprises CEO Emily Milsovic and Founder/CSO Steve Brueck, with the team operating at 1–10 employees.

Name

Daisy Genomics

Legal name

Daisy Genomics Inc.

Website

https://armonicatech.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Daisy Genomics is a privately held, seed-stage biotech developing a proprietary optical long-read DNA/RNA sequencing platform using nanofabrication and surface-enhanced Raman spectroscopy for precision medicine, targeting liquid biopsy and early cancer detection applications for clinical diagnostics firms and research institutions.

Ownership category

akta.pro rank

Product category

Optical Genomic Sequencing Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Optical DNA sequencing
• Long-read genomics
• Liquid biopsy diagnostics
• Precision medicine tools
• Epigenetic biomarker detection

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Sequencing Platform Technology: Revenue anticipated from the sale and licensing of optical sequencing technology and platform to clinical diagnostics companies and research institutions. The company aims to convert research applications into clinical diagnostic tools, positioning the platform for both research and diagnostic commercial use.
2. Diagnostic Tool Licensing: Revenue from developing and commercializing clinical diagnostic tools based on the optical sequencing platform, targeting liquid biopsy applications for cancer detection and precision medicine.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Daisy Genomics develops and commercializes a proprietary optical long-read sequencing platform built on a nanofabrication-based NGS chip and surface-enhanced Raman spectroscopy (SERS) detection. The technology enables direct DNA and RNA detection without chemical amplification and is positioned for precision medicine applications including liquid biopsy and epigenetic biomarker detection for early cancer diagnosis. The company sells and licenses the platform to clinical diagnostics firms and research institutions.

Product overview

Daisy Genomics offers a unified optical genomics platform (formerly Armonica Technologies) for precision medicine. The core product is an optical long-read sequencing technology that uses a proprietary combination of nanofabrication, semiconductor manufacturing, and surface-enhanced Raman spectroscopy (SERS) to enable direct DNA/RNA detection. The platform aims to improve accuracy, speed, and cost of detecting epigenetic biomarkers, with primary applications in liquid biopsy and clinical diagnostics.

Differentiator

Problem solved

Functional benefit

Products and services

• Optical Long-Read Sequencing Platform

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Oak Ridge National Laboratory (ORNL)coreStrategic or Co-development Partner · 7 April 2026Daisy Genomics was accepted into the Rapid Access User Program at the Center for Nanophase Materials Sciences at Oak Ridge National Laboratory. The partnership enables the company to leverage ORNL's nanofabrication and characterization capabilities for developing its proprietary next-generation sequencing chip. Initial fabrication efforts are expected to begin in the coming weeks, with plans to generate key technical data to further validate the platform.
• New Day DiagnosticscoreStrategic or Co-development Partner · 16 January 2026Daisy Genomics and New Day Diagnostics announced a strategic research collaboration, partnered with the University of Tennessee and the East Tennessee Health Innovation Alliance, to advance next-generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection. The collaboration combines New Day's clinically validated CRC liquid biopsy technology with Daisy Genomics' physics-based optical sequencing platform across New Day's CLIA-certified laboratory and university facilities.
• University of TennesseecoreStrategic or Co-development Partner · 16 January 2026The University of Tennessee supports the strategic research collaboration between Daisy Genomics and New Day Diagnostics through its facilities including the Institute for Advanced Materials & Manufacturing. The multi-institution collaboration aims to leverage the university's research infrastructure and materials science expertise to generate foundational clinical data demonstrating direct detection of epigenetic signals without chemical amplification.
• East Tennessee Health Innovation AlliancesupportingStrategic or Co-development Partner · 16 January 2026The East Tennessee Health Innovation Alliance supports the multi-institutional collaboration between Daisy Genomics and New Day Diagnostics, contributing to the goal of expanding advanced cancer screening to underserved patient populations through scalable screening tools.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Quantum-Si: Quantum-Si is commercializing a single-molecule protein detection platform and increasingly pivoting toward proteoform-level biomarker applications — an adjacent modality in next-generation optical biosensing that overlaps with Daisy's SERS-based nucleic-acid detection approach.
• Singular Genomics: Singular Genomics is developing novel benchtop and production-scale sequencing platforms (G4) targeted at clinical and translational customers — overlapping with Daisy's diagnostic use cases even though the underlying detection chemistry differs.
• Ultima Genomics: Ultima Genomics has built a $100-sequenced-genome aspirational platform targeting low-cost, high-throughput sequencing; it represents the same disruptive sequencing economics thesis that Daisy's amplification-free architecture is designed to attack.

Direct peers

• Element Biosciences: Element Biosciences is an emerging sequencing platform company (AVITI) pursuing novel, lower-cost short-read sequencing chemistry — a direct competitive entrant fighting for the same clinical sequencing customer that Daisy Genomics is targeting with its long-read platform.
• Bionano Genomics: Bionano's Saphyr system uses optical genome mapping — a physics/optics-based long-read DNA detection method — making it the closest peer in modality and methodology to Daisy Genomics' nanofluidics + SERS approach, even though its target application (structural variation) differs.
• Pacific Biosciences: Pacific Biosciences develops long-read SMRT sequencing platforms (Sequel IIe, Vega) that compete head-to-head with Daisy Genomics in the long-read clinical and translational sequencing market, particularly for applications requiring comprehensive genomic and epigenetic characterization.
• Oxford Nanopore Technologies: Oxford Nanopore offers nanopore-based long-read sequencing (MinION, PromethION, GridION) directly competitive with Daisy Genomics' long-read positioning, including emerging clinical and liquid-biopsy applications built around novel electronic/optical readout of long DNA molecules.

Broad incumbents

• Thermo Fisher Scientific: Thermo Fisher (Applied Biosystems, Ion Torrent) is a broad-life-science-tools incumbent that competes in clinical and research sequencing instrumentation; its scale, channels, and reagent ecosystem set the bar Daisy must clear to win clinical lab customers.
• Illumina: Illumina is the dominant incumbent in NGS with the broadest installed base of sequencing instruments and clinical assays; any new long-read or amplification-free platform (including Daisy's) must demonstrate compelling differentiation to displace Illumina's reagent stream and clinical workflows.

Others

• 10x Genomics: 10x Genomics provides single-cell and spatial genomics tools that are complementary, rather than directly competitive, with Daisy Genomics' sequencing platform — both companies participate in the broader advanced genomics tools ecosystem serving translational and clinical research customers.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daisy Genomics